Get started
Verona Pharma plc Sponsored ADRVerona Pharma plc Sponsored ADRVerona Pharma plc Sponsored ADR

Verona Pharma plc Sponsored ADR

No trades
See on Supercharts
Overview
Financials News Discussions Forecast Seasonals

I9SA chart


Full chart

I9SA upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪7.83 B‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.87 EUR
Net income (FY)
‪−167.59 M‬ EUR
Revenue (FY)
‪40.86 M‬ EUR
Shares float
‪78.31 M‬
Beta (1Y)
1.61

About Verona Pharma plc Sponsored ADR


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
David S. Zaccardelli
Website
veronapharma.com
Headquarters
London
Founded
2005
ISIN
US9250501064
FIGI
BBG018KMPJ83
Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. It focuses on developing inhaled ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

Check out other big names from the same industry as I9SA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

I9SA news



Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.